Ortiz-Cuaran S - Search Results

1

Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma.

Ortiz-Cuaran S, Cox D, Villar S, Friesen MD, Durand G, Chabrier A, Khuhaprema T, Sangrajrang S, Ognjanovic S, Groopman JD, Hainaut P, Le Calvez-Kelm F. Ortiz-Cuaran S, et al. Genes Chromosomes Cancer. 2013 Oct;52(10):912-9. doi: 10.1002/gcc.22086. Epub 2013 Jul 8. Genes Chromosomes Cancer. 2013. PMID: 23836507

2

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL. Gouas DA, et al. Carcinogenesis. 2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118. Epub 2010 Jun 10. Carcinogenesis. 2010. PMID: 20538734

3

Interactions between hepatitis B virus and aflatoxin B(1): effects on p53 induction in HepaRG cells.

Lereau M, Gouas D, Villar S, Besaratinia A, Hautefeuille A, Berthillon P, Martel-Planche G, Nogueira da Costa A, Ortiz-Cuaran S, Hantz O, Pfeifer GP, Hainaut P, Chemin I. Lereau M, et al. J Gen Virol. 2012 Mar;93(Pt 3):640-650. doi: 10.1099/vir.0.032482-0. Epub 2011 Nov 23. J Gen Virol. 2012. PMID: 22113009

4

Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.

Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, Gouas D, Nogueira da Costa A, Plymoth A, Khuhaprema T, Kalalak A, Sangrajrang S, Friesen MD, Groopman JD, Hainaut P. Villar S, et al. PLoS One. 2012;7(6):e37707. doi: 10.1371/journal.pone.0037707. Epub 2012 Jun 4. PLoS One. 2012. PMID: 22675488 Free PMC article.

5

TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Gouas DA, Villar S, Ortiz-Cuaran S, Legros P, Ferro G, Kirk GD, Lesi OA, Mendy M, Bah E, Friesen MD, Groopman J, Chemin I, Hainaut P. Gouas DA, et al. Carcinogenesis. 2012 Jun;33(6):1219-24. doi: 10.1093/carcin/bgs068. Carcinogenesis. 2012. PMID: 22759751 Free PMC article.

6

Association between HBX status, aflatoxin-induced R249S TP53 mutation and risk of hepatocellular carcinoma in a case-control study from Thailand.

Ortiz-Cuaran S, Villar S, Gouas D, Ferro G, Plymoth A, Khuhaprema T, Kalalak A, Sangrajrang S, Friesen MD, Groopman JD, Hainaut P. Ortiz-Cuaran S, et al. Cancer Lett. 2013 Apr 30;331(1):46-51. doi: 10.1016/j.canlet.2012.11.012. Epub 2012 Nov 27. Cancer Lett. 2013. PMID: 23200676

7

Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma.

da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, Sangrajrang S, Khuhaprema T, Mendy M, Lesi OA, Chang HK, Oh JK, Lee DH, Shin HR, Kirk GD, Merle P, Beretta L, Hainaut P. da Costa AN, et al. Int J Cancer. 2015 Jan 1;136(1):172-81. doi: 10.1002/ijc.28953. Epub 2014 May 15. Int J Cancer. 2015. PMID: 24803312 Free PMC article.

8

Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.

Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, Olivier M, Hall J, Mollereau B, Hainaut P, Bourdon JC. Marcel V, et al. Cell Death Differ. 2011 Dec;18(12):1815-24. doi: 10.1038/cdd.2011.120. Epub 2011 Sep 23. Cell Death Differ. 2011. PMID: 21941372 Free PMC article. Review.

9

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F. Fumet JD, et al. Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318514 Free PMC article.

10

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.

Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Chumbi Flores WR, Lacroix L, Loriot Y, Westeel V, Ngo-Camus M, Tissot C, Raynaud C, Gervais R, Brain E, Monnet I, Giroux Leprieur E, Caramella C, Mahier-Aït Oukhatar C, Hoog-Labouret N, de Kievit F, Howarth K, Morris C, Green E, Friboulet L, Chabaud S, Guichou JF, Perol M, Besse B, Blay JY, Saintigny P, Planchard D. Ortiz-Cuaran S, et al. Clin Cancer Res. 2020 Dec 1;26(23):6242-6253. doi: 10.1158/1078-0432.CCR-20-1037. Epub 2020 Aug 28. Clin Cancer Res. 2020. PMID: 32859654

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

41 results

Search Page